Transcallosal resection of XXXX in @entity1 with @entity302 .

@entity1 @entity410 @entity64 @entity1269 @entity73 @entity2124 @entity1017 @entity302 @entity10128 @entity2414
A variety of surgical treatments for @entity302 with @entity10128 ( @entity10128 ) are described, although most are derived from limited @entity1 experience gathered from several centres. We describe the results of transcallosal resection of @entity10128 in 29 consecutive @entity1 undergoing surgery at one centre. Twenty-nine @entity1 aged 4-23 years (mean 10 years) underwent @entity10128 surgery with a minimum of 12 months follow-up. A comprehensive, presurgical @entity302 evaluation, supplemented with endocrine and ophthalmological assessments was performed in all cases. @entity10128 were resected via a transcallosal, interforniceal approach to the third ventricle, with the assistance of frameless stereotaxy, limiting the resection to the margins of the third ventricular walls and floor and minimising traction and diathermy. Complete or near-complete (>95%) resection of the @entity10128 was achieved in 18/29 @entity1 , 75-95% resection was achieved in seven @entity1 (four of whom had complete or near-complete disconnection of residual @entity10128 ) and less than 50% resection was achieved in four. Postoperatively (follow-up 12-70 months, mean 30 months), 15 became @entity410 -free (nine off antiepileptic medication), seven had >90% reduction in @entity410 frequency, three had 55-80% reduction in @entity410 frequency, and four had less than 40% reduction in @entity410 frequency. Of 16 @entity1 who had @entity410 in the early postoperative period, six became @entity410 . No @entity1 or lesion characteristics were associated with postoperative @entity410 freedom, including features of @entity302 . Neurobehavioural improvement and resolution of EEG abnormalities were seen in the majority. Complications were @entity1269 in two, transient hypernatraemia in 17, @entity73 in 14 (persistent in four), @entity1017 in ten (persistent in five), need for supplemental thyroxine in five, and lowered @entity2124 (uncertain clinical significance) in six. Transcallosal resection of @entity10128 is an effective treatment for @entity302 , with 76% @entity1 in our @entity410 being @entity410 -free or having >90% @entity410 reduction. The operative risks include @entity64 , short-term @entity2414 , @entity1017 and minor endocrine disturbances. Based on published data, the transcallosal approach appears to be safer and more effective than other operative strategies.
